Literature DB >> 30560549

HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.

Dorhyun Johng1, Gonzalo Torga1, Charles M Ewing1, Kideok Jin2, John D Norris3, Donald P McDonnell3, William B Isaacs1.   

Abstract

BACKGROUND: The recurrent p.Gly84Glu germline mutation (G84E) in HOXB13 is consistently associated with prostate cancer (PCa), although the mechanisms underlying such linkage remain elusive. The majority of the PCa-associated HOXB13 mutations identified are localized to two conserved domains in HOXB13 that have been shown to mediate the interaction with MEIS cofactors belonging to the TALE family of homeodomain transcription factors. In this study, we sought to interrogate the biochemical and functional interactions between HOXB13 and MEIS in prostatic cells with a goal of defining how the HOXB13-MEIS complex impacts PCa pathobiology and define the extent to which the oncogenic activity of G84E is related to its effect on HOXB13-MEIS interaction/function.
METHODS: HOXB13 and MEIS paralog expression in prostate epithelial cells and PCa cell lines was characterized by qPCR and immunoblot analyses. HOXB13 and MEIS1 co-expression in human prostate tissue was confirmed by IHC, followed by co-IP mapping of HOXB13-MEIS1 interactions. Proliferation of the PCa cell line LAPC4 following shRNA-mediated knockdown of each gene or both genes was assessed using DNA- and metabolic-based assays. Transcriptional targets of HOXB13 and MEIS1 were identified by gene expression profiling and qPCR. Finally, protein stability of HOXB13 in the context of MEIS1 was determined using pulse-chase assays.
RESULTS: HOXB13 and MEIS1 are co-expressed and interact in prostate cells. Both of the putative MEIS interacting domains (MID) within HOXB13 were shown to be capable of mediating the interaction between HOXB13 and MEIS1 independently and such interactions were not influenced by the G84E mutation. The inhibitory effect of either HOXB13 or MEIS1 knockdown on cellular proliferation was augmented by knockdown of both genes, and MEIS1 knockdown abolished HOXB13-driven regulation of BCHE and TNFSF10 mRNA expression. Notably, we demonstrated that MEIS1 stabilized the HOXB13 protein in LAPC4 cells.
CONCLUSIONS: Our study provides evidence for functional HOXB13-MEIS1 interactions in PCa. MEIS1 may contribute to the cancer-promoting actions of HOXB13 in cellular proliferation and gene regulation by prolonging HOXB13 half-life. Our data demonstrates that G84E is not a loss-of-function mutation that interferes with HOXB13 stability or ability to interact with MEIS1.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  G84E; HOXB13; MEIS; PCa; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30560549     DOI: 10.1002/pros.23747

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

1.  HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.

Authors:  Xiaodong Lu; Ka-Wing Fong; Galina Gritsina; Fang Wang; Sylvan C Baca; Lourdes T Brea; Jacob E Berchuck; Sandor Spisak; Jenny Ross; Colm Morrissey; Eva Corey; Navdeep S Chandel; William J Catalona; Ximing Yang; Matthew L Freedman; Jonathan C Zhao; Jindan Yu
Journal:  Nat Genet       Date:  2022-04-25       Impact factor: 41.307

Review 2.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

3.  MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.

Authors:  Calvin VanOpstall; Srikanth Perike; Hannah Brechka; Marc Gillard; Sophia Lamperis; Baizhen Zhu; Ryan Brown; Raj Bhanvadia; Donald J Vander Griend
Journal:  Elife       Date:  2020-06-18       Impact factor: 8.140

4.  MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.

Authors:  Nichelle C Whitlock; Shana Y Trostel; Scott Wilkinson; Nicholas T Terrigino; S Thomas Hennigan; Ross Lake; Nicole V Carrabba; Rayann Atway; Elizabeth D Walton; Berkley E Gryder; Brian J Capaldo; Huihui Ye; Adam G Sowalsky
Journal:  Oncogene       Date:  2020-07-17       Impact factor: 9.867

5.  CircRNA-UCK2 Increased TET1 Inhibits Proliferation and Invasion of Prostate Cancer Cells Via Sponge MiRNA-767-5p.

Authors:  Zhendong Xiang; Chengdang Xu; Gang Wu; Bo Liu; Denglong Wu
Journal:  Open Med (Wars)       Date:  2019-11-20

6.  Oncogenic and tumor suppressor function of MEIS and associated factors.

Authors:  Birkan Gİrgİn; Medine KaradaĞ-Alpaslan; Fatih KocabaŞ
Journal:  Turk J Biol       Date:  2020-12-14

7.  Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.

Authors:  Adam B Weiner; Farzana A Faisal; Elai Davicioni; R Jeffrey Karnes; Donald J Vander Griend; Tamara L Lotan; Edward M Schaeffer
Journal:  Eur Urol Oncol       Date:  2020-06-12

8.  FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.

Authors:  Lin Zhang; Yicong Wan; Zihan Zhang; Yi Jiang; Jinghe Lang; Wenjun Cheng; Lan Zhu
Journal:  RNA Biol       Date:  2020-11-05       Impact factor: 4.652

Review 9.  Epidemiology and genomics of prostate cancer in Asian men.

Authors:  Yao Zhu; Miao Mo; Yu Wei; Junlong Wu; Jian Pan; Stephen J Freedland; Ying Zheng; Dingwei Ye
Journal:  Nat Rev Urol       Date:  2021-03-10       Impact factor: 14.432

10.  Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.

Authors:  W Nathaniel Brennen; Yezi Zhu; Ilsa M Coleman; Susan L Dalrymple; Lizamma Antony; Radhika A Patel; Brian Hanratty; Roshan Chikarmane; Alan K Meeker; S Lilly Zheng; Jody E Hooper; Jun Luo; Angelo M De Marzo; Eva Corey; Jianfeng Xu; Srinivasan Yegnasubramanian; Michael C Haffner; Peter S Nelson; William G Nelson; William B Isaacs; John T Isaacs
Journal:  JCI Insight       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.